KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Total Debt (2019 - 2025)

Rigel Pharmaceuticals (RIGL) has 7 years of Total Debt data on record, last reported at $82.1 million in Q4 2025.

  • For Q4 2025, Total Debt rose 22.63% year-over-year to $82.1 million; the TTM value through Dec 2025 reached $82.1 million, up 22.63%, while the annual FY2025 figure was $82.1 million, 22.63% up from the prior year.
  • Total Debt reached $82.1 million in Q4 2025 per RIGL's latest filing, up from $59.7 million in the prior quarter.
  • Across five years, Total Debt topped out at $82.1 million in Q4 2025 and bottomed at $19.8 million in Q1 2021.
  • Average Total Debt over 5 years is $48.2 million, with a median of $59.6 million recorded in 2023.
  • Peak YoY movement for Total Debt: surged 101.89% in 2021, then fell 0.05% in 2025.
  • A 5-year view of Total Debt shows it stood at $19.9 million in 2021, then surged by 98.09% to $39.4 million in 2022, then skyrocketed by 51.09% to $59.6 million in 2023, then increased by 12.33% to $67.0 million in 2024, then rose by 22.63% to $82.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Debt were $82.1 million in Q4 2025, $59.7 million in Q3 2025, and $59.8 million in Q2 2025.